Evestia Clinical - the new brand identity for EMAS Pharma

Evestia Clinical has today been announced as the new identity of EMAS Pharma. The new identity reaffirms Evestia Clinical’s focus on delivering high-quality clinical trials for its biotech clients, especially in oncology and rare diseases, where there is an urgent need for innovation and speed.

Evestia Clinical was acquired from Bionical EMAS in December 2024 by Kester Capital and an experienced incoming leadership team including Richard Barfield (Chairman), Lewis Cameron (CEO), Roy Ovel (CCO), and Carl Hvass (CFO). Evestia Clinical has over 25 years of experience in providing innovative, patient-centric clinical trial services for its biotech clients across the world.

“The launch of Evestia Clinical marks an exciting new chapter in our journey,” said Richard Barfield, Chairman. “Our leadership team has a proven track record of driving growth in the CRO sector, and with the support of Kester Capital, we are well-positioned to accelerate our expansion, strengthen our service offerings, and broaden our global reach. We are building a world-class platform that will deliver exceptional value to our biotech clients.”

“We are committed to providing our clients with the most effective and adaptive clinical trial solutions,” said Lewis Cameron, CEO. “This transformation aligns with our long-term vision of being the preferred CRO partner for biotech companies focused on complex, high-impact research areas.”

Adam Maidment, Managing Partner at Kester Capital, commented:

“Kester has been investing in CROs for over a decade, and we see Evestia Clinical as a highly strategic platform in a dynamic and fast-growing global market. We are delighted to be partnering once again with Richard, Lewis, Roy, Carl, and the existing Evestia Clinical team to support the next phase of growth - both organically and through acquisition as they continue to drive innovation in clinical research.”